

Title (en)

Benzothiophene formulations of a specific dosage

Title (de)

Benzothiophenformulierung einer bestimmten Dosierung

Title (fr)

Formulation de benzothiophènes à une dose spécifique

Publication

EP 0781555 A1 19970702 (EN)

Application

EP 97200262 A 19930726

Priority

- EP 93305860 A 19930726
- US 92093392 A 19920728

Abstract (en)

A pharmaceutical unit dosage form is provided, comprising from 50 to 200 mg of a benzothiophene, preferably raloxifene, or a pharmaceutically-acceptable salt thereof.

IPC 1-7

A61K 31/4535; **A61P 19/08**; **A61P 19/10**

IPC 8 full level

A61K 31/38 (2006.01); **A61K 9/20** (2006.01); **A61K 9/48** (2006.01); **A61K 31/167** (2006.01); **A61K 31/365** (2006.01); **A61K 31/381** (2006.01); **A61K 31/40** (2006.01); **A61K 31/4025** (2006.01); **A61K 31/425** (2006.01); **A61K 31/445** (2006.01); **A61K 31/453** (2006.01); **A61K 31/4535** (2006.01); **A61K 31/453** (2013.01 - EP US); **A61K 31/4535** (2013.01 - EP US); **A61K 31/55** (2013.01 - EP US); **A61K 31/55** (2013.01 - EP US); **A61K 31/56** (2013.01 - EP US); **A61K 31/56** (2006.01); **A61K 31/56** (2006.01); **A61P 19/10** (2006.01); **A61P 43/00** (2006.01); **C07D 333/56** (2006.01)

CPC (source: EP US)

A61K 9/0095 (2013.01 - EP US); **A61K 9/2054** (2013.01 - EP US); **A61K 9/2059** (2013.01 - EP US); **A61K 9/4866** (2013.01 - EP US); **A61K 31/381** (2013.01 - EP US); **A61K 31/40** (2013.01 - EP US); **A61K 31/4025** (2013.01 - EP US); **A61K 31/425** (2013.01 - EP US); **A61K 31/445** (2013.01 - EP US); **A61K 31/453** (2013.01 - EP US); **A61K 31/4535** (2013.01 - EP US); **A61K 31/55** (2013.01 - EP US); **A61K 31/56** (2013.01 - EP US); **A61P 5/24** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 19/08** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

C-Set (source: EP US)

1. **A61K 31/4025 + A61K 2300/00**
2. **A61K 31/453 + A61K 2300/00**
3. **A61K 31/55 + A61K 2300/00**
4. **A61K 31/56 + A61K 2300/00**

Citation (applicant)

- US 4133814 A 19790109 - JONES C DAVID, et al
- US 4418068 A 19831129 - JONES CHARLES D [US]

Citation (search report)

- [XYD] US 4418068 A 19831129 - JONES CHARLES D [US]
- [XY] US 5075321 A 19911224 - SCHREIBER ALAN D [US]
- [X] A.U. BUZDAR ET AL.: "Phase II evaluation of Ly156758 in metastatic breast cancer", ONCOLOGY, vol. 45, 1988, pages 344 - 345, XP002028378

Cited by

US7964734B2; US6710059B1; US8609695B2; US7005428B1; US8389548B2; US6670346B1; US7429576B2; US6465445B1; US7884092B2; US7943603B2; US8188066B2

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

EP 0584952 A1 19940302; **EP 0584952 B1 19970502**; AT E152351 T1 19970515; AT E359074 T1 20070515; AU 4422193 A 19940203; AU 658075 B2 19950330; AU 658075 C 19940203; BG 61429 B1 19970829; BG 97982 A 19940429; BR 9303013 A 19940216; CA 2101356 A1 19940129; CA 2101356 C 19981117; CN 1054742 C 20000726; CN 1088205 A 19940622; CY 2044 B1 19980430; CY 2599 B2 20100303; CZ 149893 A3 19940413; CZ 281913 B6 19970312; DE 19975012 I2 20030522; DE 69310288 D1 19970605; DE 69310288 T2 19970911; DE 69334132 D1 20070524; DE 69334132 T2 20071220; DK 0584952 T3 19971013; DK 1438957 T3 20070730; EP 0781555 A1 19970702; EP 1438957 A1 20040721; EP 1438957 B1 20070411; EP 1772150 A1 20070411; ES 2102602 T3 19970801; ES 2283939 T3 20071101; GR 3024171 T3 19971031; HK 90197 A 19970801; HU 219233 B 20010328; HU 9302163 D0 19931028; HU T65707 A 19940728; IL 106450 A0 19931115; IL 106450 A 19991231; JP 2749247 B2 19980513; JP 3162662 B2 20010508; JP H06199665 A 19940719; JP H10114656 A 19980506; KR 0161300 B1 19981201; KR 940005270 A 19940321; LU 90334 I2 19990223; MX 9304432 A 19940531; MY 111188 A 19990930; NL 980044 I1 19990301; NL 980044 I2 19990601; NO 1999006 I1 19990414; NO 303863 B1 19980914; NO 932650 D0 19930722; NO 932650 L 19940131; NZ 248210 A 19970624; NZ 314686 A 20000728; NZ 504611 A 20050729; PH 30032 A 19961108; PL 177348 B1 19991029; PL 299814 A1 19940207; PT 1438957 E 20070622; RO 113212 B1 19980529; RU 2104697 C1 19980220; SA 93140340 B1 20040828; SG 45315 A1 19980116; TW 366342 B 19990811; UA 26213 C2 19990719; US 2003212058 A1 20031113; US 5393763 A 19950228; US 5457117 A 19951010; US 5534527 A 19960709; US 6906086 B2 20050614; ZA 935283 B 19950123

DOCDB simple family (application)

EP 93305860 A 19930726; AT 04101615 T 19930726; AT 93305860 T 19930726; AU 4422193 A 19930727; BG 9798293 A 19930722; BR 9303013 A 19930727; CA 2101356 A 19930727; CN 93117097 A 19930728; CY 0800014 A 20080813; CY 9802044 A 19980430; CZ 149893 A 19930723; DE 19975012 C 19930726; DE 69310288 T 19930726; DE 69334132 T 19930726; DK 04101615 T 19930726; DK 93305860 T 19930726; EP 04101615 A 19930726; EP 07100202 A 19930726; EP 97200262 A 19930726; ES 04101615 T 19930726; ES 93305860 T 19930726; GR 970401816 T 19970718; HK 90197 A 19970626; HU 9302163 A 19930726; IL 10645093 A 19930722; JP 18596593 A 19930728; JP 25893797 A 19970924; KR 930014329 A 19930727; LU 90334 C 19981223; MX 9304432 A 19930722;

MY PI19931475 A 19930727; NL 980044 C 19981223; NO 1999006 C 19990414; NO 932650 A 19930722; NZ 24821093 A 19930721;
NZ 31468693 A 19930721; NZ 50461100 A 20000518; PH 46555 A 19930722; PL 29981493 A 19930727; PT 04101615 T 19930726;
RO 9301066 A 19930728; RU 93048466 A 19930727; SA 93140340 A 19931113; SG 1996003394 A 19930726; TW 82100153 A 19930112;
UA 93003166 A 19930723; US 18052294 A 19940112; US 32939694 A 19941026; US 42209695 A 19950414; US 44621003 A 20030527;
ZA 935283 A 19930721